Advertisement
Table 4 Comparison of patients’ characteristics and elimination efficacy
| Trial/Reference | Banares [10] | Kribben [19] | Sponholz MARS [7] | Sponholz SPAD [7] | Own study |
|---|---|---|---|---|---|
| Device | MARS | Prometheus | MARS | SPAD | ADVOS |
| Patients’ characteristics | |||||
| Clinical setting | 19 ICUs | 10 ICUs | Surgical ICU | Medical ICU | |
| Type of LF | |||||
| - ACLF | 100% | 100% | 56% | 64% | |
| - ALF | - | - | 28% | - | |
| - “secondary” LF | - | - | - | 36% | |
| - Graft failure | - | - | 16% | - | |
| (CLIF)-SOFA | 8 ± 3 | 10 ± 3 | 13 ± 4 | 15 ± 3 | |
| MELD | 26 ± 8 | 28 ± 10 | 34 ± 7 | ||
| Child-Pugh | 11 ± 2 | 12 ± 1 | 12 ± 1 | ||
| Efficacy analysis | |||||
| No. of treatments for efficacy analysis | 4 | 8 (mean) | 2.2 (mean) | 2.2 (mean) | 1 |
| Delta-Bilirubin relative | −26% (day 4) | −23% (day 28) | −23% | −23% | −32% |
| Delta-Bilirubin absolute [mg/dL] | −8.7 (day 4) | −6 (day 28) | −4.3 | −4.2 | −8.3 |
| Delta-creatinine relative | −20% (day 4) | −13% (day 28) | −18% | +5% | −27% |
| Delta-creatinine absolute [mg/dL] | −0.3 (day 4) | −0.2 (day 28) | −0.4 | +0.1 | −0.6 |
| Delta-BUN relative | n.d. | n.d. | −9% | +5% | −37% |
| Delta-BUN absolute [mg/dL] | n.d | n.d. | −12 | +8 | −18 |
| Maximum number of treatments | 10 | 11 | 4 | 4 | 101 |
